EviCure
Extracellular Vesicles-based Platform for the Treatment of Cancer
Company Overview
Snapshot
Founded in February 2023, EviCure operates with 1–10 employees and has raised $760.7K across four funding rounds from one investor. The company secured funding in May 2026, with Peregrine Ventures participating.
Business overview
EviCure is a Health Tech & Life Sciences company developing a novel extracellular vesicle (EV)-based platform technology for cancer treatment. The company leverages AI capabilities and sophisticated human cancer disease models to achieve robust and specific anti-tumor effects against a wide range of solid tumors. EviCure's EVs can also serve as vehicles for targeted delivery of RNA-based therapies, peptides, and small therapeutic molecules, generating combined approaches that target multiple oncogenic pathways. The company has developed a groundbreaking AI-driven approach for scaling EV production, ensuring consistent and reproducible anti-tumor effects. Its first product, PL-Ex-1, is being developed as an EV treatment for lung cancer and other solid tumors.
Company Intelligence Q&A
- What is EviCure's primary focus in cancer treatment?
- EviCure is developing a novel extracellular vesicle (EV)-based platform technology for cancer treatment, utilizing AI and human cancer disease models to achieve robust and specific anti-tumor effects against solid tumors.
- How does EviCure ensure consistent production of its therapeutic EVs?
- EviCure has developed a groundbreaking approach for scaling up EVs using artificial intelligence (AI) algorithms and biological sensors, ensuring consistent and reproducible production while maintaining their anti-tumor effects.
- What is PL-Ex-1?
- PL-Ex-1 is the first product on EviCure’s platform, designed as a leading EV treatment against lung cancer, offering a safe, cost-effective, mutation-agnostic, and stage-independent treatment for various types of lung and other solid tumors.
- When did EviCure last receive funding?
- EviCure received funding in May 2026, with Peregrine Ventures participating in the round.
- What was EviCure's first disclosed funding event?
- EviCure secured funding in January 2024, with Peregrine Ventures leading the round.